Candel Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
CADL$9.49+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| YEAR ENDED DECEMBER 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $19,314 | $24,506 |
| General and administrative | 14,057 | 13,885 |
| Total operating expenses | 33,371 | 38,391 |
| Loss from operations | (33,371) | (38,391) |
| Other income (expense): | ||
| Interest income | 1,086 | 2,081 |
| Interest expense | (2,090) | (2,595) |
| Change in fair value of warrant liability | (20,802) | 966 |
| Total other income (expense), net | (21,806) | 452 |
| Net loss and comprehensive loss | $(55,177) | $(37,939) |
| Net loss per share, basic and diluted | $(1.74) | $(1.31) |
| Weighted-average common shares outstanding, basic and diluted | 31,675,076 | 28,935,289 |
Candel ThErapeutics, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.